Shares of Orexigen Therapeutics Inc. continued to fall Wednesday amid a tangle of negative headlines following the decision to terminate the ongoing cardiovascular outcomes trial (CVOT) for obesity drug Contrave (naltrexone and bupropion), as clinical investigators criticized the company’s early release of data and partner Takeda Pharmaceutical Co. Ltd. launched a formal dispute process seeking, among other changes, to shift more of the financial responsibility for the cost of a new CVOT to Orexigen.